


RECEIVED
MAR 02 2001
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on February 23, 2001.


Cathy Stearns

#7
JRP
2/27/01

Applicant : John A. Arcadi
Application No. : 09/383,114
Filed : August 25, 1999
Title : COMPOSITION AND METHOD FOR
TREATING PROSTATE CANCER

Grp./Div. : 1614
Examiner : J. Goldberg

Docket No. : 35687/RWJ/H29

RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Post Office Box 7068
Pasadena, CA 91109-7068
February 23, 2001

Commissioner:

In response to the Office action dated 10/23/00.

REMARKS

Claims 1-27 stand rejected as unpatentable over the Arcadi references (1986 and 1990).

The attached Declaration of Lawrence W. Jones, M.D., the Director of Prostate Research Program at Huntington Medical Research Institutes (HMRI), the assignee of this application, shows that even very limited clinical trials to date have produced a substantial decrease in PSA measurements for 6 out of 12 volunteers, and that for 2 of the volunteers, the drop exceeded 50%, which has been reported by an independent source as indicating that survival time for those two patients will be significantly extended. See the reference referred to in the attached Declaration,